Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.
Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.
The company will apply artificial intelligence to a large clinical and genomic dataset from VA records in order to support personalized clinical decision making.
De-identified data from the study, which will look at 10,000 samples by whole-exome sequencing, will be made available for general research use.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
Genomiser correctly prioritized causal variants in as much as 68 percent of experimental cases, improving on numbers from comparable tools like Phen-Gen.
The updated repository includes 265 drugs, 1,074 cell lines, as well as associated whole-exome sequencing and gene expression data among other datasets.
A collaboration between the Broad Institute and Microsoft Research has created machine learning-derived rules to improve on-target efficiency.
The new center will help accelerate personalized medicine efforts and support a collaborative research ecosystem in Europe.
Tamr's software may help researchers involved in the project to organize, unify, and integrate large quantities of genomic and other data for analysis.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.